Replies to post #52099 on Biotech Values

[dewophile]

i think its a pretty safe bet to say dyloject will get reimbursed at a premium..its quite a unique situation where even at a multiple per unit cost compared with the existing generic option the product actually saves the system money, which will hold particular sway in a nationalized healthcare environment

i also don't understand why the company modeled their revenue projections using a 20-35% market share - it seems awfully conservative - i mean why would anyone, ever, still use voltarol once dyloject is on formulary - it works faster, is better tolerated, and offers a cost savings to boot